03/12/2019
It gives us immense pleasure to announce that Roche Is rolling out Early Access Program for SMA Type1.
It is result of CureSMA India’s constant Advocacy, Meeting and Workshop with Roche India.
In continuity to CureSMA India’s commitment to bring treatment for sma patients in India, Roche has agreed to provide access to Roche Solution: Risdiplam , through a support program, the Early Access Program for SMA Type 1.
Roche Global and Roche India are committed to providing an early access to SMA type 1 patients through the treating doctor.
Please ask your child’s treating doctor to send your application to Roche at the email Id india.medinfo@roche.com.
Only SMA type 1 kids can apply for early access at present but we are still requesting for types 2 and 3, and will keep members updated.
The age of applicant should be more than 2 months and it’s mandatory to have confirmed genetic diagnosis report and number of smn2 copies report.
We shall keep advocating for the broader access for all the sma patients across the age and type.
CureSMA India is committed to providing support and treatment to all SMA patients and we are happy that the efforts and prayers are becoming fruitful. We are extremely grateful to partner with Roche on all their initiatives.
